Mass-DAC

The Massachusetts Data Analysis Center (Mass-DAC), was a data-coordination center active 2002 through 2017, in response to a state mandate, provides expert evaluation of cardiac surgery and angioplasty data  in the Commonwealth of Massachusetts.  Mass-DAC collected and validated patient-specific clinical data from all Massachusetts hospitals that provide cardiac surgery or percutaneous coronary interventions.  This data was used to monitor the quality of cardiac care delivered in the Commonwealth to improve the level of care provided.

In appreciation for Dr. Normand's contributions as Director of Mass-DAC, she was honoured with the Outstanding Lifetime Achievement Award by the Council on Quality of Care and Outcomes Research (QCOR) of the American Heart Association (AHA) at the QCOR Annual Meeting in April 2017. 

In 2012, Dr. Normand received the Distinguished Scientist award from the American Heart Association due to her national and international leadership in the development of innovative statistical methods for health services and outcomes research.  John Rumsfeld MD, PhD, former QCOR chair, said:

“Normand has demonstrated leadership in her field, and the impact of her work has been far-reaching. Her unique combination of high-level scholarship, creativity and remarkable interpersonal skills has led her work to change the way investigators approach their own research. Without question, she is considered one of the preeminent biostatisticians in the country and is certainly among the most influential individuals in health services and outcomes research.”


Mass-DAC Publications:

  1. Shahian DM, Normand S-LT, Torchiana DF, Lewis SM, Pastore JO, Kuntz RE, Dreyer PL. Cardiac surgery report cards: Comprehensive review and statistical critique. Annals of Thoracic Surgery 2001; 72(6):2155-2168.
  2. Shahian DM, Normand S-LT. The volume-outcome relationship: From Luft to Leapfrog. Annals of Thoracic Surgery 2003; 75:1048-1058.
  3. Shahian DM, Torchiana DF, Shemin RJ, Rawn JD, Normand, S-LT. The Massachusetts cardiac surgery report card: implications of statistical methodology. Annals of Thoracic Surgery 2005; 80:2106-2113.
  4. Shahian DM, Torchiana DF, Normand S-LT. Implementation of a cardiac surgery report card. Annals of Thoracic Surgery 2005; 80:1146-1180.
  5. Shahian DM, Silverstein T, Lovett AF, Wolf RE, Normand S-LT. Comparison of clinical and administrative data sources for hospital coronary artery bypass graft surgery report cards. Circulation 2007; 115:1518-1527.
  6. Normand S-LT, Shahian DM. Statistical and clinical aspects of institutional profiling. Statistical Science 2007; 22(2):206-226.
  7. Timbie JW, Newhouse JP, Rosenthal MB, Normand S-LT. A cost-effectiveness framework for profiling the value of hospital care. Medical Decision Making 2008; 28(3):419-34.
  8. Shahian DM, Normand S-LT. The comparison of "risk-adjusted" hospital outcomes. Circulation 2008; 117:1955-1963.
  9. Normand S-LT. Some old and some new statistical tools for outcomes research. Circulation 2008; 118(8):872-884.
  10. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, Resnic FS, Normand S-LT. Long-term clinical outcomes following drug-eluting and bare metal stenting in Massachusetts. Circulation 2008; 118:1817-1827.
  11. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand S-LT. Drug-eluting or bare-metal stents for acute myocardial infarction. New England Journal of Medicine 2008; 359(13):1330-42.
  12. Garg P, Normand S-LT, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare metal stenting in patients with diabetes mellitus: Results from the Mass-DAC registry. Circulation 2008; 118(22):2277-85.
  13. Timbie JW, Shahian DM, Newhouse JP, Rosenthal MB, Normand S-LT. Composite measures for hospital quality using quality-adjusted life years. Statistics in Medicine 2009; 28(8):1238-1254.
  14. Castellanos LR, Normand S-LT, Ayanian JZ. Racial and Ethnic Disparities in Access to Higher and Lower Quality Cardiac Surgeons for Coronary Artery Bypass Grafting. The American Journal of Cardiology 2009; 103:1682-1686.
  15. Stevens L-M, Khairy P, Agnihotri AK. Coronary Artery Bypass Grafting After Recent or Remote Percutaneous Coronary Intervention in the Commonwealth of Massachusetts. Circulation: Cardiovascular Interventions 2010; 3:460-467.
  16. Charytan, DM, Varma,MR, Silbaugh, TS, Lovett, AF, Normand, S-LT, Mauri, L. Long-term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients With Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. American Journal of Kidney Diseases 2011; 57(2):202-211.
  17. Barringhaus KG, Zelevinsky K, Lovett A, Normand S-LT, Ho KKL. Impact of Independent Data Adjudication on Hospital-Specific Estimates of Risk-Adjusted Mortality Following Percutaneous Coronary Interventions in Massachusetts. Circulation: Cardiovascular Quality and Outcomes 2011; 4:92-98.
  18. Peterson ED. Editorial: The Need for "Compassionate Provider Profiling": Refining Risk Assessment for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2011; 57:912-913.
  19. Resnic FS, Normand S-LT, Piemonte TC, Shubrooks SJ, Zelevinsky K, Lovett A, Ho KKL. Improvement in Mortality Risk Prediction after Percutaneous Coronary Intervention through the Addition of a "Compassionate Use" Variable to the National Cardiovascular Data Registry CathPCI Dataset: A Study from the Massachusetts Angioplasty Registry. Journal of the American College of Cardiology 2011; 57:904-911.
  20. Yeh RW, Normand S-LT, Wolf RE, Jones PG, Ho KKL, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA. Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention. Circulation 2011; 124:1557-1564.
  21. Shahian DM, Iezzoni LI, Meyer GS, Kirle L, Normand S-LT. Hospital-wide mortality as a quality metric: conceptual and methodological considerations. American Journal of Medical Quality 2012; 27(2):112-23.
  22. Yeh RW, Normand S-LT, Wang Y, Barr CD, Dominici F. Geographical disparities in the incidence and outcomes of hospitalized myocardial infarction: does a rising tide lift all boats? Circulation Cardiovascular Quality and Outcomes 2012; 5(2):197-204. PMC3310945.
  23. Stamou SC, Robich M, Wolf RE, Lovett A, Normand S-LT, Selke FW. Effects of gender and ethnicity on outcomes after aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery 2012; 144(2):486-492.
  24. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012; 172(15):1145-52.
  25. Venkatesan DV, Matheny ME, Govindarajulu US, Normand S-LT, Robbins SL, Agarwal VV, Bangalore S, Resnic FS. Vascular Closure Devices in Contemporary Practice. Journal of the American College of Cardiology: Cardiovascular Interventions 2012; 5(8):837-844.
  26. Yeh RW, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour D, Lovett A, Weiner B, Jacobs AK, Normand S-LT. Sources of hospital variation in short term readmission rates after percutaneous coronary intervention. Circulation Interventions 2012; 5(2):227-236.
  27. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand S-LT. Bayesian methods affirm use of percutaneous coronary angiography intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013; 127(22):2177-85.
  28. Kramer DB, Kennedy KF, Noseworthy PA, Buxton AE, Josephson ME, Normand S-L, Spertus JA, Zimetbaum PJ, Reynolds MR, Mitchell SL. Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Journal of the American College of Cardiology 2013; 6(4):488-97.
  29. Wasfy J, Yeh R, Mauri L, Normand, S-L, Zelevinsky K, Lovett A. A Prediction Model to Identify Patients at High Risk for 30-Day Readmission after Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes 2013; 6(4):429-35.
  30. Jacobs AK, Normand S-LT, Massaro JM, et al. Nonemergency PCI at hospitals with or without onsite cardiac surgery. New England Journal of Medicine 2013; 368:1498-508.
  31. Wasfy JH, Strom JB, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand S-L, Mauri L, Yeh RW. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014; 7(1):97-103.
  32. Yeh RW, Vasaiwala S, Forman DE; Silbaugh TS, Zelevinski K, Lovett A, Normand S-LT, Mauri L. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circulation: Cardiovascular Quality and Outcomes. 2014; 7(1):118-24.
  33. Albert MA, Ayanian JZ, Silbaugh TS, Lovett A, Resnic F, Jacobs A, Normand S-LT. Early Results of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care. Circulation 2014; DOI: CIRCULATIONAHA.113.005231. 2014 April 11. [Epub ahead of print]
  34. Alameddine AK, Visintainer P, Normand S-LT, Wolf RE, Alameddine YA. Cancer rates in adults after cardiac interventions: a preliminary observational report. American Journal of Clinical Oncology. doi: 10.1097/COC.0000000000000120 2014 Sep 5. [Epub ahead of print]
  35. Bangalore S, Silbaugh TS, Normand S-LT, Lovett AF, Welt FG, Resnic FS. Drug-eluting stents versus bare metal stents prior to noncardiac surgery. Catheter Cardiovascular Interventions 2015; 85(4):533-41.
  36. Spertus JV, Normand S-LT, Wolf RE, Cioffi M, Lovett A, Rose S. Assessing Hospital Performance Following Percutaneous Coronary Intervention Using Big Data. Circ Cardiovasc Qual Outcomes. 2016 Nov 8; DOI: CIRCOUTCOMES.116.002826. [Epub ahead of print]

 

Mass-DAC Presentations:

  1. Normand S-L. Limitations of Analyses in Continuous Quality Improvement: Accuracy. American College of Cardiology Scientific Sessions. March 2005.
  2. Stevens L. Coronary Artery Bypass Grafting after Uneventful Percutaneous Coronary Intervention in the Commonwealth of Massachusetts. American Heart Association Scientific Sessions, November 2007.
  3. Shapira O. The Association of Race and of Insurance with Utilization and Outcomes after Coronary Artery Bypass Grafting Surgery in Massachusetts. American Heart Association Scientific Sessions, November 2007.
  4. Mauri L. Long-Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts. American Heart Association Scientific Sessions, November 2007.
  5. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand S-LT. Long-Term Clinical Outcomes Following Drug-Eluting and Bare-Metal Stenting for Acute Myocardial Infarction in Massachusetts. American College of Cardiology Scientific Sessions, March 2008.
  6. Garg P, Normand S-LT, Silbaugh T, Wolf R, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L.  Drug-eluting or bare metal stenting in patients with diabetes mellitus: Results from the Mass-DAC registry. American Heart Association Scientific Sessions, November 2008.
  7. Sakhuja R, Silbaugh T, Varma M, Normand S-L, Mauri L. Drug-Eluting Stent Use in Acute Myocardial Infarction: Do Data Drive Practice? American College of Cardiology Scientific Sessions. March 2009.
  8. Barringhaus KG, Zelevinsky K, Lovett A, Normand S-L, Ho KKL. Impact of Independent Data Adjudication on Hospital-Specific Estimates of Risk-Adjusted Mortality Following Percutaneous Coronary Interventions in Massachusetts. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2009.
  9. Anis A, Normand S-L, Wolf RE, Lovett A, Mauri L, Patel N, and Jacobs AK. Outcomes Following Primary Percutaneous Coronary Intervention: A Comparison between Hospitals with and without Cardiac Surgery On-Site. American Heart Association Scientific Sessions. November 2009.
  10. Charytan DM, Varma MR, Silbaugh TS, Lovett AF, Normand S-LT, Mauri L. Long term Clinical Outcomes Following Drug-Eluting or Bare-Metal Stent Placement in Patients with Severely Reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. American Heart Association Scientific Sessions. November 2009.
  11. Khurana R. Independent US Validation of the British Columbia PCI Risk Score. American College of Cardiology Scientific Sessions. March 2010.
  12. Forman DE, Vasaiwala S, Silbaugh TS, Lovett A, Normand S-L, Mauri L. Acute and 3-year Bleeding Risks: Comparing Drug-Eluting to Bare-Metal Stents in Old and Very Old Adults in a Community Population. American Heart Association Scientific Sessions. November 2010.
  13. Yeh RW, Zelevinsky K, Normand S-LT, Sakhuja R, Lovett A, Weiner BH, Rosenfield KA. 30-Day All-Cause Readmission After Percutaneous Coronary Intervention in Massachusetts: Clinical Predictors and Hospital-Variation of a New Quality Metric. American Heart Association Scientific Sessions. November 2010.
  14. Ali MJ, Nedeljkovic ZS, Zelevinsky K, Lovett A, Normand S-LT, Jacobs AK. Mortality in STEMI Patients Undergoing Inter-Hospital Transfer for Primary PCI in Massachusetts. American Heart Association Scientific Sessions. November 2010.
  15. Albert MA, Silbaugh TS, Ayanian JZ, Lovett A, Wolf RE, Zelevinsky K, Resnic F, Normand S-LT. Impact of Massachusetts Health Care Reform on Racial, Ethnic, and Socioeconomic Disparities in Cardiovascular Care. American Heart Association Scientific Sessions. November 2010.
  16. Normand S-LT, Treacy S. Silbaugh, Zelevinsky K, Wolf RE, Cioffi M, Lovett A, Resnic FS, Ho KKL. Hospital Quality Following Percutaneous Coronary Intervention: Massachusetts Experience From 2003-2007. American Heart Association Scientific Sessions. November 2010.
  17. Kato NS, Cioffi M, Normand S-LT. Implantable Cardioverter Defibrillator Usage in the Commonwealth of Massachusetts – A 10 Year Study. American Heart Association Scientific Sessions. November 2010.
  18. Kato NS, Cioffi M, Normand S-LT. Unsupported Implantable Cardioverter Defibrillator Use in the Commonwealth of Massachusetts - 1997 to 2008. American Heart Association Scientific Sessions. November 2010.
  19. Cubeddu RJ, Lago RM, Zelevinsky K, Lovett AF, Mendoza I, Crane AM, Witzke CF, Normand S-LT, Pomerantsev E, Palacios IF. No Mortality Advantage of “On” versus “Off”-hours Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Results from the Massachusetts Data Analysis Center Registry. American Heart Association Scientific Sessions. November 2010.
  20. Normand S-LT, Silbaugh TS, Zelevinsky K, Wolf RE, Cioffi M, Lovett A, Resnic FS, Ho KKL. Hospital-quality Following Percutaneous Coronary Intervention: Massachusetts Experience From 2003-2007. American College of Cardiology Scientific Sessions. May 2010.
  21. Anis A, Normand S-LT, Wolf RE, Lovett A, Mauri L, Patel N, and Jacobs AK. Primary Percutaneous Coronary Intervention With or Without Cardiac Surgery On-Site: Massachusetts’ Experience. American Heart Association Scientific Sessions. November 2010.
  22. Yeh RW, Jones PG, Wolf RE, Normand S-LT, Cohen DJ, Ho KKL, Cutlip DE, Kugelmass AD, Spertus JA. Predicting the Restenosis Benefit of Drug-Eluting vs. Bare Metal Stenting Prior to Angiography: A Tool for Patients and Clinicians. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2010.
  23. Kato NS, Cioffi M, Normand S-LT. Internal Cardioverter Defibrillator Utilization in the Commonwealth of Massachusetts - 1997 to 2008. American College of Cardiology Scientific Sessions. March 2011.
  24. Vasaiwala S, Normand S-LT, Silbaugh TS, Forman D, Baron S, Lovett A, Mauri L. Impact of Completeness of Revascularization on Late Mortality in an Unrestricted Patient Population Undergoing Percutaneous Coronary Intervention with Drug-Eluting or Bare-Metal Stents. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
  25. Forman D, Vasaiwala S, Silbaugh TS, Lovett A, Normand S-LT, Mauri L. Assessing utility of drug-eluting stents in coronary patients aged 85 years and older. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
  26. Yeh RW, Normand S-LT, Mauri L, Wolf RE, Cohen DJ, Ho KKL, Spertus JA. Does the Expected Reduction in Restenosis from Drug-Eluting Stents Predict Actual Use? An Assessment of Treatment-Risk Paradox Using the C-statistic. American Heart Association Quality of Care and Outcomes Research Scientific Sessions. May 2011.
  27. Vasaiwala S, Forman D, Yeh RW, Silbaugh TS, Lovett A, Normand S-LT, and Mauri L. Selective Drug-Eluting Stent Use in Elderly Patients: Impact on Percutaneous Coronary Intervention Mortality and Bleeding Risk. American College of Cardiology Scientific Sessions. March 2012.
  28. Cubeddu R, Lago R, Zelevinsky K, Lovett A, Mendoza I, Crane A, Witzke C, Normand S-L, Pomerantsez E, Palacio I. No Mortality Advantage of “On” versus “Off”-hours Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Results from the Massachusetts Data Analysis Center Registry.
  29. Sarma A, Normand S-LT, Hatfield L, Matheny M, Resnic F. The Learning Curve for Medical Devices: Experience with Vascular Closure Devices in Massachusetts. American College of Cardiology Scientific Sessions. March 2013. American Heart Association Scientific Sessions. November 2012.
  30. Yeh RW, Mauri L, Wold R, Romm I, Lovett A, Normand S-L. Steep Declines in Population Rates of Coronary Revascularization. American Heart Association Scientific Sessions. November 2013.
  31. Yeh RW, Mauri L, Wolf RE, Romm IK, Biondolillo M, Lovett A, Normand S-LT. Steep Declines in Population Rates of Coronary Revascularization. American College of Cardiology Scientific Sessions. March 2014.
  32. Adhikari S, Normand S-L T. Non-parametric Bayesian Instrumental Variable Analysis: Comparing effectiveness of radial vs femoral arteries access Percutaneous Coronary Intervention (PCI) in reducing bleeding and vascular complications. EMR-IBS and Italian Region Conference. May 2017.